Loading...
 
Mediterr J Rheumatol 2023;34(3):282-3
Tofacitinib as a Promising Therapeutic Option in Refractory Autoimmune-Mediated Vascular and Sclera Inflammation
Authors Information

4th Department of Internal Medicine, Hippokration Hospital, School of Medicine, Aristotle University Thessaloniki, Greece

T Dimitroulas

Abstract
This paper has no abstract.

Cite this article as: Dimitroulas T. Tofacitinib as a Promising Therapeutic Option in Refractory Autoimmune-Mediated Vascular and Sclera Inflammation. Mediterr J Rheumatol 2023;34(3):282-3.

 

Article Submitted: 22 Sep 2023; Article Accepted: 24 Sep 2023; Available Online: 29 Sep 2023

 

This work is licensed under a Creative Commons Attribution 4.0 International License.

©2023 The Author(s).

https://doi.org/10.31138/mjr.20230929.taa